LA, v. K., M, M., M, S., J, P., W, T., EFC, v. R., . . . WP, B. (2026). Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population. Gastro hep advances, 5(5), 100912. https://doi.org/10.1016/j.gastha.2026.100912
Chicago Style (17th ed.) CitationLA, van Kleef, et al. "Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population." Gastro Hep Advances 5, no. 5 (2026): 100912. https://doi.org/10.1016/j.gastha.2026.100912.
MLA (9th ed.) CitationLA, van Kleef, et al. "Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population." Gastro Hep Advances, vol. 5, no. 5, 2026, p. 100912, https://doi.org/10.1016/j.gastha.2026.100912.
